Mydrilate (Cyclopentolate Hydrochloride Bp)

Cyclopentolate Hydrochloride, the active ingredient in Mydrilate, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It produces pupil dilation (mydriasis) and cycloplegia to facilitate eye examinations and refraction testing in patients of all ages clinically.

GNH USA supplies Mydrilate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Customers benefit from reliable lead times and dedicated technical support.

Mydrilate (cyclopentolate hydrochloride) is used in ophthalmology to achieve pharmacologic dilation and cycloplegia.

Induction of mydriasis for ocular examinations: provides pupil dilation to allow thorough fundus and retinal evaluation. Cycloplegia for refraction assessment: temporarily paralyzes accommodation to enable accurate measurement of refractive error. Adjunct in the management of anterior uveitis: facilitates examination and reduces spasm of the iris sphincter.

Mydrilate may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Transient stinging or burning on instillation - Mild conjunctival hyperemia - Temporary blurred vision

Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Severe allergic reaction (e.g., angio‑edema, anaphylaxis) - Systemic anticholinergic toxicity (dry mouth, tachycardia, confusion)

When prescribing Mydrilate, consider the following precautions.

Assess intraocular pressure before use: avoid in patients with narrow-angle glaucoma. Screen for hypersensitivity: discontinue if allergic signs appear. Use with caution in pediatric patients: systemic absorption may be higher. Avoid concurrent use with other mydriatics: may exacerbate dilation. Monitor for systemic anticholinergic effects: especially in elderly or compromised patients. Store at room temperature: keep in original container, protect from light and moisture.

Mydrilate can interact with other medications; review patient medication lists carefully.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents: may increase systemic anticholinergic load. - Combination with adrenergic mydriatics (e.g., phenylephrine): can cause excessive pupil dilation and hypertension. - Use with drugs that lower intraocular pressure (e.g., prostaglandin analogues): may counteract desired effect.

Moderate Interactions (Monitor Closely): - Systemic beta‑blockers: may mask tachycardia from anticholinergic effect. - Topical anesthetics: may enhance corneal irritation. - Oral antihistamines: additive anticholinergic side‑effects.